Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Travis Mickle
|
| gptkbp:dateOfNameChange |
2023
|
| gptkbp:focusesOn |
rare diseases
central nervous system disorders prodrug development |
| gptkbp:foundedIn |
2006
|
| gptkbp:founder |
Travis Mickle
|
| gptkbp:headquartersLocation |
gptkb:Celebration,_Florida,_United_States
gptkb:Coralville,_Iowa,_United_States |
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
APADAZ
AZSTARYS |
| gptkbp:numberOfEmployees |
less than 100
|
| gptkbp:renamed |
Zevra Therapeutics
|
| gptkbp:tradedOn |
NASDAQ: KMPH
|
| gptkbp:website |
https://www.kempharm.com/
|
| gptkbp:bfsParent |
gptkb:Orphazyme
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
KemPharm
|